REVIEWUse of Psychotropic Medications in the HIV-Positive Patient Part IIVergara-Rodriguez, Pamela MD; Watts, Jeff MDEditor(s): Janicak, Philip G. MD, Editor Author Information Dr. Vergara-Rodriguez is Internist/Psychiatrist, and Dr. Watts is Clinic Psychiatric Coordinator, Ruth M. Rothstein CORE Center, 2020 W. Harrison Street, Chicago, IL 60612; E-mail: [email protected]. Dr. Vergara-Rodriguez has disclosed that she has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. Dr. Watts has disclosed that he is/was a member of the speakers bureaus of Abbott Virology and BMS Virology. The authors also have disclosed that the use of venlafaxine, duloxetine, pregabalin, gabapentin, and tricyclic antidepressants for the treatment of HIV peripheral neuropathy as discussed in this article has not been approved by the U.S. Food and Drug Administration. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Psychopharm Review: October 2008 - Volume 43 - Issue 10 - p 75-81 doi: 10.1097/01.IDT.0000337881.32001.3b Buy CE Test Metrics © 2008 Lippincott Williams & Wilkins, Inc.